Aspire Biopharma Surges After SEC Filings and Launch of Phase 1 High-Dose Aspirin Trial

Introduction

Aspire Biopharma Holdings Inc (NASDAQ: ASBP) is an early-stage pharmaceutical technology company formed in September 2021. Headquartered in Humacao, Puerto Rico, and New York, Aspire develops patent-pending sublingual and nano-formulation drug delivery systems designed to bypass the gastrointestinal tract. Its technology enables rapid absorption under the tongue and can be applied to analgesics, supplements, treatments for erectile dysfunction, and therapies for traumatic brain injury.

Corporate Structure

Aspire employs approximately 51–200 people, combining scientific research, regulatory affairs, and commercial development teams. CEO Kraig Higginson leads corporate strategy and investor relations. Since its inception, Aspire has secured two patent applications with the U.S. Patent and Trademark Office: one filed on March 28, 2023 (application No. 63/456,290) covering its fast-acting powder formulation, and a second filed on October 23, 2024 (application No. 63/702,381) for high-dose aspirin delivery using micelle-based technology.

Sublingual delivery by Jaehyun Kim

Key Developments

• On April 9, 2025, Aspire initiated its Phase 1 single-center clinical study of a fast-acting, high-dose aspirin formulation delivered via its oral transmucosal system.
• Institutional Review Board approval for that protocol was granted on April 29, 2025.
• The company began initial production of a single-dose, sublingual pre-workout supplement on April 11, 2025.
• CEO Kraig Higginson presented at the Emerging Growth Conference on April 17, 2025, and is scheduled to speak at the Sidoti Virtual Investor Conference on May 21, 2025, at 2:30 p.m. EDT.
• Aspire completed its merger with PowerUp Acquisition Corp. on September 3, 2024, and began trading under the ticker ASBP on the NASDAQ Global Market.
• On November 14, 2025, Aspire filed its quarterly reports (Form 10-Q and amended 10-Q/A) and a Current Report (Form 8-K) with the U.S. Securities and Exchange Commission.

Financial and Strategic Analysis

As of November 17, 2025, ASBP shares closed at $0.1218, marking a 33.41% increase on volume of 103,623,072 shares. The increase followed the company’s November 14 SEC filings, which typically include updated financial statements and management discussions. Aspire’s strategic priorities include advancing its aspirin formulation through clinical trials, expanding its patent portfolio, and exploring partnerships to apply its delivery platform across multiple therapeutic areas. Continued investment in research and development and regulatory progress will influence its cash runway and potential for licensing revenue or co-development agreements.

Market Position and Industry Context

Aspire operates in the drug delivery segment of the biopharmaceutical industry, where sublingual and transmucosal technologies address the need for rapid-onset therapies. Its platform targets pain management and could extend to other markets such as erectile dysfunction and neuroprotection. The company’s mid-stage pipeline, coupled with patent protection, positions it among a growing number of firms innovating beyond traditional oral or injectable formulations. Competition includes established pharmaceutical delivery divisions and emerging biotech firms focused on non-invasive administration routes.

tl;dr

On November 14, 2025, Aspire Biopharma filed its Form 10-Q, amended 10-Q/A, and Form 8-K, resulting in a 33.41% increase in its share price to $0.1218 on November 17. Earlier in 2025, the company received Institutional Review Board approval (April 29), launched a Phase 1 high-dose aspirin trial (April 9), and began production of a sublingual pre-workout supplement (April 11). Kraig Higginson will present at Sidoti on May 21, 2025. Aspire is awaiting clinical trial results and further regulatory feedback into 2026.